Skip to main content
TipRanks
Go Ultimate75% OFF

Rezolute (6HV1) AI Stock Analysis

1 Followers
DE:6HV1

Rezolute

(Frankfurt:6HV1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Phase 3 efficacy signalThe preliminary upLIFT results provide a strong clinical signal for ersodetug in tumor hyperinsulinism, including substantial reductions in intravenous glucose dependence. If confirmed in final analysis, this could support regulatory progress and establish meaningful differentiation in a high-need rare disease market.
Negative Factors
Pre-revenue lossesRezolute has not yet established a commercial revenue base, leaving its earnings profile dependent on successful clinical development and eventual approval. Persistent, widening losses reduce internal funding capacity and make future profitability contingent on converting pipeline progress into a marketable product.

Rezolute (6HV1) vs. iShares MSCI Germany ETF (EWG)

-100%-80%-60%-40%-20%0%20%DE:6HV1-55.74%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 353.54M
Dividend Yield
―
Average Volume (3M)
426
Price to Earnings (P/E)
-4.8
Beta (1Y)
1.03
Revenue Growth
―
EPS Growth
23.90%
Country
Germany
Employees
63
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Rezolute Business Overview & Revenue Model

Company Description

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal an...

Rezolute Risk Analysis

Rezolute disclosed 31 risk factors in its most recent earnings report. Rezolute reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we advance through clinical trials may not have favorable results in later clinical trials.Q1, 2025

Rezolute Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:6HV1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ABUSABUS70Outperform$626.97M3.62129.13%―1142.57%―
XNCRXNCR61Neutral$2.78B-23.62-21.29%―33.55%11.51%
TSHATSHA54Neutral$1.34B-9.53-51.87%―-13.07%-23.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GERNGERN51Neutral$622.98M-13.79-22.27%―18.60%37.60%
KODKOD50Neutral$7.27B-27.25-287.64%――0.88%

* Healthcare Sector Average

Performance Comparison

0%200%400%DE:6HV1GERNABUSXNCRKODTSHADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:6HV1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:6HV1Rezolute, Inc.3.74-4.86-56.51%
GERNGeron Corporation0.97-0.16-14.42%
ABUSArbutus Biopharma4.09-0.45-9.91%
XNCRXencor Inc.37.0921.47137.45%
KODKodiak Sciences111.1991.36460.72%
TSHATaysha Gene Therapies, Inc.4.10-0.02-0.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.